RPAP3 enhances cytotoxicity of doxorubicin by impairing NF-kappa B pathway

Biochem Biophys Res Commun. 2011 Jan 28;404(4):910-4. doi: 10.1016/j.bbrc.2010.12.071. Epub 2010 Dec 22.

Abstract

Activation of anti-apoptotic gene transcription by NF-κB (nuclear factor-kappa B) has been reported to be linked with a resistance of cancer cells against chemotherapy. NEMO (NF-κB essential modulator) interacts with a number of proteins and modulates the activity of NF-κB pathway. In this study, we revealed that RPAP3 (RNA polymerase II-associated protein 3) possesses an activity to bind with NEMO and to inhibit the ubiquitination of NEMO and that RPAP3 enhances doxorubicin-induced cell death in breast cancer cell line T-47D through the marked impairment of NF-κB pathway. These results indicate that RPAP3 may be a novel modulator of NF-κB pathway in apoptosis induced by anti-cancer chemotherapeutic agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / pharmacology*
  • Apoptosis Regulatory Proteins
  • Apoptosis*
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism*
  • Cell Line, Tumor
  • Doxorubicin / pharmacology*
  • Humans
  • I-kappa B Kinase / metabolism
  • NF-kappa B / metabolism*
  • Phosphorylation
  • Ubiquitination

Substances

  • Antibiotics, Antineoplastic
  • Apoptosis Regulatory Proteins
  • Carrier Proteins
  • IKBKG protein, human
  • NF-kappa B
  • RPAP3 protein, human
  • Doxorubicin
  • I-kappa B Kinase